ALSE Financials 07/16/2014 14:44:23 Alseres Pharm

ALSE Financials 07/16/2014 14:44:23
Alseres Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 474 531 - -
Cost of Revenue - - - -
Gross Profit 474 531 - -
Operating Expenses
Research and Development - 51 93 465
Sales, General and Admin. 1,038 1,692 1,472 2,657
Non-Recurring Items - - - -
Other - - - -
Operating Income (565) (1,212) (1,565) (3,123)
Income From Continuing Operations
Add'l Income/Expense Items 78 1 521 6,279
Earnings Before Interest and Tax (487) (1,211) (1,521) (3,121)
Interest Expense 455 435 1,838 2,644
Earnings Before Tax (942) (1,645) (3,359) (5,765)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (942) (1,645) (2,882) 512
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (942) (1,645) (2,882) 512
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (942) (1,645) (2,882) 512